Is Cohance Life overvalued or undervalued?

As of November 9, 2022, Cohance Life is considered overvalued with a high PE ratio of 100.54 and an EV to EBITDA of 71.77, despite similar metrics to its peer Suven Pharmaceuticals, and its recent performance has declined by -9.38% year-to-date compared to the Sensex's 5.56% gain.

As of 9 November 2022, Cohance Life has moved from expensive to very expensive, indicating a significant shift in valuation perception. The company is currently overvalued, as evidenced by its high PE ratio of 100.54, an EV to EBITDA ratio of 71.77, and a Price to Book Value of 15.87. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peer, Suven Pharmaceuticals Ltd., which has a similar PE ratio of 100.54 and an EV to EBITDA of 71.77, Cohance Life's valuation appears excessive. The company's return metrics, with a ROCE of 17.56% and ROE of 15.79%, do not justify such high valuation multiples. Furthermore, while the stock has outperformed the Sensex over the long term, recent performance shows a decline, with a year-to-date return of -9.38% compared to the Sensex's 5.56%. This reinforces the view that the stock is overvalued in the current market context.

Who are in the management team of Cohance Life?

As of March 2022, the management team of Cohance Life includes Venkateswarlu Jasti (Managing Director), J V Ramudu (Chairman), and several independent and non-executive directors, ensuring a diverse governance structure.

As of March 2022, the management team of Cohance Life includes the following individuals:<BR><BR>1. Venkateswarlu Jasti - Managing Director<BR>2. Deepanwita Chattopadhyay - Independent Director<BR>3. V Sambasiva Rao - Independent Director<BR>4. Jerry Jeyasingh - Non-Executive & Non-Independent Director<BR>5. Hanumantha Rao Kokkonda - Company Secretary<BR>6. D G Prasad - Independent Director<BR>7. J V Ramudu - Chairman & Non-Executive Director<BR>8. Shweta Jalan - Non-Executive Director<BR>9. U B Pravin Rao - Independent Director<BR><BR>This team comprises a mix of executive and independent directors, along with a company secretary, contributing to the governance and strategic direction of the company.

When is the next results date for Cohance Life?

No Upcoming Board Meetings

What is the bonus history of the Cohance Life?

Cohance Life issued a 1:1 bonus on September 25, 2020, with a record date of September 28, 2020, allowing shareholders to double their holdings by receiving an additional share for each share owned.

Cohance Life has a bonus history that includes a 1:1 bonus issue announced on September 25, 2020. The record date for this bonus was September 28, 2020. This means that for every share held, shareholders received an additional share, effectively doubling their holdings at that time.

Has Cohance Life declared dividend?

Cohance Lifesciences Ltd has declared a 100% dividend, amounting to 5 per share, but the dividend yield is 0%. While the company has shown significant price appreciation over various periods, it has not consistently provided dividend returns.

Cohance Lifesciences Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 5<BR>- Ex-date: 09 Sep 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -19.08%, with a dividend return of 0%, resulting in a total return of -19.08%.<BR><BR>Over the past year, the price return was 66.12%, with a dividend return of 0%, leading to a total return of 66.12%.<BR><BR>In the last 2 years, the price return was 122.25%, with a dividend return of 0%, resulting in a total return of 122.25%.<BR><BR>For the 3-year period, the price return was 115.92%, with a dividend return of 1.09%, culminating in a total return of 117.01%.<BR><BR>In the 4-year period, the price return was 103.18%, with a dividend return of 1.90%, leading to a total return of 105.08%.<BR><BR>Over the last 5 years, the price return was 539.98%, with a dividend return of 0%, resulting in a total return of 539.98%.<BR><BR>Overall, while Cohance Lifesciences Ltd has declared a dividend, the dividend yield remains at 0%. The total returns over various periods indicate significant price appreciation, particularly over the longer term, despite the lack of consistent dividend returns.

Who are the peers of the Cohance Life?

Cohance Life's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Gland Pharma, J B Chemicals, Pfizer, Emcure Pharma, and Wockhardt. Cohance Life has excellent management risk, while its 1-year return is 68.83%, significantly higher than Emcure Pharma's N/A return.

Peers: The peers of Cohance Life are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Gland Pharma, J B Chemicals &, Pfizer, Emcure Pharma, and Wockhardt.<BR><BR>Quality Snapshot: Excellent management risk is observed at Cohance Life, while Good management risk is found at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Gland Pharma, J B Chemicals &, Pfizer, and Emcure Pharma. Below Average growth is noted at Divi's Lab., Torrent Pharma, Gland Pharma, and Cohance Life, while Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs. The Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Gland Pharma, J B Chemicals &, Cohance Life, and Pfizer, while Good is noted for Torrent Pharma and Emcure Pharma, and Below Average for Wockhardt.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Wockhardt at 174.76%, while the lowest is Emcure Pharma, which has an N/A return. Cohance Life's 1-year return is 68.83%, which is significantly positive compared to the lowest peer. Additionally, Gland Pharma and Emcure Pharma have negative six-month returns.

What does Cohance Life do?

Cohance Lifesciences Ltd is a CDMO in the Pharmaceuticals & Biotechnology sector, providing services to major life science companies. As of March 2025, it reported net sales of 4,020 Cr and a net profit of 420 Cr, with a market cap of INR 40,632 Cr.

Overview:<BR>Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company in the Pharmaceuticals & Biotechnology industry, serving leading global life science and fine chemical majors.<BR><BR>History:<BR>Cohance Lifesciences Ltd was incorporated as Suven Pharmaceuticals Limited (SPL). The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 4,020 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 420 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 40,632 Cr (Large Cap) <BR><BR>Key Metrics:<BR>P/E: 152.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 15.79% <BR>Price to Book: 23.75 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the top shareholders of the Cohance Life?

The top shareholders of Cohance Life include Berhyanda Limited with 33.34%, mutual funds with 8.65%, foreign institutional investors at 7.38%, Jasti Property And Equity Holdings Private Limited with 6.59%, and individual investors holding 6.63%.

The top shareholders of Cohance Life include several key players. The majority shareholder is Berhyanda Limited, which holds a significant 33.34% of the company. Additionally, mutual funds collectively hold 8.65% through 28 schemes, while foreign institutional investors (FIIs) account for 7.38% with 167 different FIIs involved. The highest public shareholder is Jasti Property And Equity Holdings Private Limited, with a stake of 6.59%. Individual investors also have a notable presence, holding 6.63% of the shares.

How big is Cohance Life?

As of 24th July, Cohance Lifesciences Ltd has a market capitalization of 39,974.00 Cr, with recent net sales of 1,197.58 Cr and a net profit of 267.87 Cr. The latest balance sheet shows shareholder's funds of 2,050.66 Cr and total assets of 2,254.09 Cr.

As of 24th July, Cohance Lifesciences Ltd has a market capitalization of 39,974.00 Cr, categorizing it as a Large Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 1,197.58 Cr and a Net Profit of 267.87 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 2,050.66 Cr and Total Assets of 2,254.09 Cr.

Are Cohance Life latest results good or bad?

Cohance Lifesciences' latest results show strong sales growth of 87.55% year-on-year, reaching Rs 1,389.73 crore. However, profitability has declined significantly, with a 47% drop in profit before tax and rising interest expenses, indicating potential financial challenges.

Cohance Lifesciences' latest results present a mixed picture. On one hand, the company has achieved impressive net sales of Rs 1,389.73 crore, reflecting a substantial year-on-year growth of 87.55%. This indicates a strong demand for its products and a positive sales trajectory.<BR><BR>However, there are significant concerns regarding profitability. The profit before tax has decreased by 47% compared to the average of the previous four quarters, and profit after tax has also fallen by 41.1%. Additionally, the operating profit margin has declined to 20.39%, which is the lowest it has been in five quarters. <BR><BR>The surge in interest expenses by over 312% suggests that the company is facing increased borrowing costs, which could strain its financial health further. The rising debt-equity ratio of 0.16 times indicates potential liquidity challenges.<BR><BR>In summary, while Cohance Lifesciences shows strong sales growth, the decline in profitability and rising costs present significant challenges that could impact its overall financial stability.

Is Cohance Life technically bullish or bearish?

As of October 27, 2025, Cohance Life's technical trend has shifted to a moderate bearish stance, supported by bearish indicators across MACD, Bollinger Bands, and moving averages, alongside a significant 1-year decline of -31.85%.

As of 27 October 2025, the technical trend for Cohance Life has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this conclusion include a bearish MACD on the weekly chart, bearish Bollinger Bands on both weekly and monthly time frames, and a bearish moving average on the daily chart. Additionally, the Dow Theory indicates a mildly bearish trend on both weekly and monthly levels. The stock's recent performance shows a significant decline, with a 1-year return of -31.85%, further supporting the bearish outlook.

How has been the historical performance of Cohance Life?

Cohance Life has demonstrated significant growth, with net sales rising to 2,608.50 Cr in March 2025 from 1,051.35 Cr in March 2024, and profit after tax increasing to 484.24 Cr. Despite a decline in operating profit margin, the company shows strong operational performance and a robust financial trajectory.

Answer:<BR>Cohance Life has shown significant growth in its historical performance, particularly in net sales and profit metrics. <BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Cohance Life reported net sales of 2,608.50 Cr, a substantial increase from 1,051.35 Cr in March 2024 and 1,340.33 Cr in March 2023. The total operating income mirrored this growth, reaching 2,608.50 Cr in March 2025, compared to 1,051.35 Cr in the previous year. The company's total expenditure also rose to 1,811.44 Cr in March 2025 from 645.54 Cr in March 2024, primarily driven by increased raw material costs and employee expenses. Operating profit (PBDIT) for March 2025 was reported at 866.27 Cr, up from 467.72 Cr in March 2024, indicating a strong operational performance despite a decline in operating profit margin to 30.56% from 38.6%. Profit before tax increased to 642.63 Cr in March 2025, while profit after tax reached 484.24 Cr, reflecting a growth from 300.28 Cr in March 2024. The company's total assets grew to 3,031.20 Cr in March 2025, up from 2,254.09 Cr in March 2024, with total liabilities also increasing to 3,031.20 Cr. Cash flow from operating activities was 288.00 Cr in March 2025, down from 358.00 Cr in March 2024, but the company ended with a net cash inflow of 38.00 Cr, compared to a net outflow of 17.00 Cr in the previous year. Overall, Cohance Life's financial trajectory indicates robust growth and operational scaling over the years.

Should I buy, sell or hold Cohance Life?

Which are the latest news on Cohance Life?

Why is Cohance Life falling/rising?

As of 04-Dec, Cohance Lifesciences Ltd's stock price is rising to Rs. 549.90, but the overall outlook remains bearish due to a year-to-date decline of 51.48%, declining investor participation, and concerning financial metrics despite a short-term uptick.

As of 04-Dec, Cohance Lifesciences Ltd's stock price is rising, currently at Rs. 549.90, reflecting an increase of Rs. 6.35 or 1.17%. This uptick comes after a trend reversal, as the stock has gained following four consecutive days of decline. Additionally, it has outperformed its sector by 0.88% today. However, it is important to note that the stock recently hit a new 52-week low of Rs. 540.5, indicating ongoing volatility.<BR><BR>Despite the current rise, the stock has shown poor performance over longer periods, with a year-to-date decline of 51.48% and a staggering 57.63% drop over the past year. The stock is also trading below all its moving averages, which suggests a bearish trend overall. Furthermore, there has been a significant decrease in investor participation, with delivery volume falling by 69.7% compared to the five-day average, indicating a lack of confidence among investors.<BR><BR>The company's financial health presents mixed signals. While it boasts high management efficiency with a return on equity (ROE) of 21.07% and a low debt-to-equity ratio, its long-term growth prospects are concerning. The operating profit has only grown at an annual rate of 4.15% over the past five years, and recent financial results have shown a decline in key metrics, including a 42.4% drop in profit before tax compared to the previous four-quarter average.<BR><BR>Moreover, the stock's valuation appears expensive relative to its peers, trading at a price-to-book value of 5.6, which may deter potential investors. The fact that 100% of promoter shares are pledged adds further risk, as this can exert additional downward pressure on the stock in a falling market.<BR><BR>In summary, while there is a short-term rise in the stock price, the overall outlook remains bearish due to poor long-term performance, declining investor participation, and concerning financial metrics.